Disposition of oral azithromycin in humans

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 6, 1997, Pages 641-648

  Luke, David R ^a,b   Foulds, George ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DRUG METABOLITE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; HUMAN EXPERIMENT; ILEOSTOMY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HUMANS; ILEOSTOMY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 0031011327     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90098-9     Document Type: Article

References (23)

1. Bright GM, Nagel AA, Bordner J, Desai KA, Dibring JN, Nowakowska J, et al. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivatives: a new class of macrolide antibiotics, the azalides. J Antibiot 1988;41:1029-47.
2. Rodvold KA, Piscitelli SC. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin Infect Dis 1993;17:S192-9.
3. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(suppl A):73-82.
4. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370-4.
5. Foulds G, Connolly AG, Fortner JH, Fletcher AM. Separation of presystemic and postabsorptive influences on the bioavailability of azithromycin in Cynomolgus monkeys. Program and Abstracts of the Third International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portugal, January 24-26, 1996.
6. Shepard RM, Duthu GS, Ferraina RA, Mullins MA. High-performance liquid Chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J Chromatogr B Biomed Appl 1991;565: 321-37.
7. Mindel A, Carney O. Acyclovir malabsorption. Br Med J 1988;296:1605.
8. Backman L, Beerman B, Groschinsky-Grind H, Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet 1979; 4:63-8.
9. Knight GC, Macris MP, Peric M, Ducan JM, Frazier OH, Cooley DA. Cyclosporin A pharmacokinetics in a cardiac allograft recipient with jejunoileal bypass. Transplant Proc 1988;20:351-5.
10. Heizer WD, Pittman AW, Hammond JE, Fitch DD, Bustrack JA, Hull JH. Absorption of digoxin from tablets and capsules in subjects with malabsorption syndromes. Ann Pharmacother 1989;23:764-9.
11. Victor A, Odlind V, Krai JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987;16:483-91.
12. Broyles JE, Brown RO, Self T, Fredrick RC, Luther RW. Nortriptyline absorption in short bowel syndrome. J Parenter Enteral Nutr 1990;14:326-7.
13. Lehman ME, Kolb KW, Barnhart GR, Wagman LD, Barr WH. Warfarin absorption in a patient with short-bowel syndrome. Clin Pharm 1985;4: 325-6.
14. Höffler D, Koeppe P, Paeske B. Pharmacokinetics of azithromycin in normal and impaired renal function. Infection 1995;23:356-61.
15. Foulds G, Ferraina RA, Fouda HG, Johnson RB, Kamel AM, Shepard RM, Falcone R, Hanna C. Azithromycin concentrations in gallbladder, hepatic tissue, and bile following a five-day regimen in man. Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 17-20, 1993.
16. Foulds G, Shepard RM, Allen RH, Ferraina RA, Fletcher AM. Transintestinal elimination of azithromycin in dogs. Program and Abstracts of Fifth European Congress of Clinical Microbiology and Infectious Diseases, Oslo, Norway, September 9-11, 1991.
17. Luke DR, Foulds G, Cuddigan FM, Levy B, Cohen SF, Shoup RE. Azithromycin safety, toleration, and pharmacokinetics after intravenous administration. Program and Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
18. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin. J Antimicrob Chemother 1990;25:39-47.
19. Walsh JA, Warren KW. Selective primary health care: an interim strategy for disease control in developing countries. N Engl J Med 1979;301:967-74.
20. Guerrant RL. Principles and syndromes of enteric infection. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1985:837-51.
21. Kitzis MD, Goldstein FW, Miégi M, Acar JF. In vitro activity of azithromycin against various Gramnegative bacilli and anaerobic bacteria. J Antimicrob Chemother 1990;25:15-8.
22. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21:536-41.
23. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection [abstract]. Gastroenterology 1995;108:A826.